A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Study Summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Conditions

TP53 Y220C Mutation Advanced Solid Tumors

Interventions / Drugs

metformin hydrochloride 500 mg tablet rosuvastatin 10 mg tablet repaglinide 0.5 mg tablet midazolam hydrochloride syrup rezatapopt

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment14 participants

Primary Completion—

Lead SponsorPMV Pharmaceuticals, Inc

Data Retrieved2026-04-11 04:24:42.345876+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.